ArticleEndocrine2021
Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Development of a sensitive plasma lenvatinib quantification method and validation in thyroid cancer patients.Journal of the Endocrine Society · 2026Article
- Administration of multikinase inhibitor followed by radioiodine therapy for poorly differentiated thyroid cancer: a case description and systematic review.Quantitative imaging in medicine and surgery · 2026Article
- Adjuvant External Beam Radiotherapy Reduces Local Recurrence in Poorly Differentiated Thyroid Cancer : A Multicenter Retrospective Cohort Study Describing Outcomes in the Treatment of Resectable Poorly Differentiated Thyroid Cancer.Annals of surgical oncology · 2025Article
- Predictors of response to lenvatinib in advanced differentiated thyroid cancer: focus on the CONUT score.Endocrine · 2025Article
- Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study).European thyroid journal · 2025Observational
- Navigating the complexity of current interventional radiological approaches for distant metastases in thyroid cancer.Frontiers in endocrinology · 2025Review
- Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency.Frontiers in endocrinology · 2025Article
- Real world outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma.European thyroid journal · 2024Article
- Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer.European thyroid journal · 2024Article
- Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm.European thyroid journal · 2023Article
- Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma.European thyroid journal · 2023Article
- Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects.Journal of the Endocrine Society · 2022Article
- 2-[Diagnostics (Basel, Switzerland) · 2022Article
- Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report.Surgical case reports · 2022Article
- Daily Management of Patients on Multikinase Inhibitors' Treatment.Frontiers in oncology · 2022Review
- Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.International journal of molecular sciences · 2021Review
- Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.Endocrine · 2021Article
- Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLenvatinib (LEN) has been approved for the treatment of patients with progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). Real-life studies reported a lower progression-free survival (PFS) than the registration study, likely due to the more advanced stage of tumors, the more frequent pretreatment with other TKIs, the limited follow-up, and the worse clinical condition of the patients included.
methodsWe evaluated the clinical data of our cohort of 13 consecutive patients, all receiving LEN as a first-line TKI treatment, and followed-up in a single tertiary Center.
resultsAll patients had an ECOG of 0-1 and regional or distant metastases were documented in 61.5% and 77% of patients, respectively. Median PFS was 22 months (95% CI 14-35) with partial response in 69% and stable disease in 31% of patients. All patients experienced at least one adverse event (AE), the most frequent being fatigue, anorexia, diarrhea, and hypertension. The daily dose was reduced in 70% of patients and only one patient (7.7%) discontinued the drug for AEs.
conclusionIn this series of RAI-R DTC patients, with the unique features to have an ECOG 0 or 1 and to be naive for TKI treatments, PFS was the longest among all real-life published so far, with the highest rate of patients with partial response and one of the lowest drug discontinuation rate for AEs. The correct timing of treatment start, the tailoring of the dose, and a proper management of the AEs may have a significant impact on the treatment response to LEN.
Indexed as
Identifiers
32885329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.